divis
rais estim top anoth organ growth quarter
adjust ep sept yoy vs record cent forecast
greater-than-anticip margin sale includ organ growth second consecut
factor out-performance ep estim
ep estim least project held
back somewhat like difficult prior-year comparison especi first half fiscal year
leader infect prevent equip medic institut report sept adjust ep
vs year earlier compar report year-over-year period yoy unless otherwis
indic cent estim
revenu increas million price contribut bp constant currenc organ growth
 revenu corpor total increas million flat
million ireland recent move corpor headquart ireland
avoid potenti tax issu brexit rose
adjust gross profit rose million increas bp sale due product
initi price fx partial off-set higher labor cost adjust sg expens
million revenu vs expens equal revenu vs adjust
oper profit million equal revenu vs tax rate around
vs adjust net incom increas million net margin rose sale vs
healthcar product sale infect prevent procedur solut
healthcar provid world-wide includ capit equip washer steam ga steril surgic
tabl light clean chemistri relat mainten instal servic well consum
pleas see import disclosur end report
organ constant currenc basi million backlog slip yoy
million pipelin order healthi capit equip rose consum increas
servic rose approxim busi replac remain project
consum track procedur volum equip align building/rehab project
oper profit increas million group margin vs due increas
volum favor product mix
healthcar specialti servic rang specialti servic healthcar provid includ
hospit steril servic instrument scope repair linen manag
organ oper profit rose million vs million group margin
vs high volum partial off-set invest increas capac outsourc
instrument reprocess continu impact segment result depend level invest
particular quarter smaller outsourc project work gener return month
well larger project involv build new facil staf etc may take year reach
optim margin start-up natur longer term project result lumpi segment
appli steril technolog ast contract steril laboratori servic medic
devic manufactur pharmaceut custom other million sale rose
organ increas volum segment core medic devic custom benefit recent
capac addit sever competitor ethylen oxid eo ga facil temporarili perman
close due environment concern although benefit modestli eo facil
run near full capac nine eo facil around twice global
believ eo use safe done properli expect eo use continu use around one-
half single-us medic devic global along limit abil substitut radiat ga steril
group oper profit million group oper margin revenu vs
due revenu growth inflationari price includ busi
contract offset higher labor cost increas product
life scienc ls consist capit equip consum product washer steril
etc equip mainten specialti servic pharmaceut manufactur research
institut lumpi busi due variabl construct deliveri schedul rose
organ million capit equip decreas due difficult prior-year comparison growth
consum servic ls backlog rose million ls longer lead
time ls oper profit decreas million group margin vs
consum highest margin follow servic capit equip
balanc sheet septemb includ cash equival million equiti billion
debt billion provid debt-to-tot capit ratio vs slightli
ebitda comfort rang
flow oper cfo quarter million vs million year earlier
million year-to-d vs million primarili target tuck-in acquisit free cash flow
project million million previous million due higher cap-
ex plan see dividend rais august quarterli rate cent per
share consecut annual increas approxim million share repurchas
quarter leav around million remain board author share repurchas use off-set
pleas see import disclosur end report
divis wellington shield co llc
sale earn outlook
continu benefit growth medic procedur complex procedur addit
procedur done outpati basi requir construct new facil use product
along new product launch last fiscal year well least plan fiscal year
growth-rel invest expect impact segment current quarter
dec ep estim vs last year previous revenu million
ep estim vs record compani rais guidanc
previou project revenu nearli billion
target constant currenc organ growth fiscal year sever small
acquisit add around million cent ep fx million headwind sale fourth
quarter face challeng comparison organ growth oper incom rose
model oper margin record vs gross free cash flow
estim per share respect assum net incom million million
exclud intang amort around million alreadi deduct adjust net
incom figur capital-expenditure million million expand global capac ast
outsourc instrument reprocess capital-expenditure mainten around million dividend
ep estim revenu billion assum
continu solid hospit spend continu see oper margin model
bp revenu long-term target organ growth double-
share trade forward ep estim project
year growth rate rate hold due valuat metric investor focus
strong fundament includ effect manag healthi hospit spend potenti outsourc
 margin improv initi rel immun polit pressur healthcar
compani may wish aggress sell ev-to-ebitda ratio project
ebitda million project ebitda million share trade price-to-earnings
ratio base upon trail report ep current
global hospit spend environ key variabl deriv approxim revenu
outsid subject compani increas geograph risk well vagari foreign currenc
fluctuat medic technolog compani product obsolesc and/or increas competit
relev risk regulatori issu continu import mani compani product process
subject fda approv and/or inspect
pleas see import disclosur end report
divis wellington shield co llc
march fiscal year-end
mm ex per share
good sold
good sold
compani report great lake review estim cleveland oh elliott schlang jason rodger
pleas see import disclosur end report
march fiscal year-end
mm ex per share
total
cfo net incom
after-tax return averag asset
after-tax return averag equiti
pre-tax return average invest capit
compani report great lake review estim cleveland oh elliott schlang jason rodger
pleas see import disclosur end report
